Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.

GLP-1 receptor agonists may increase the risk of several autoimmune diseases in adults with type 2 diabetes, according to ...

AOU data comprised electronic health records (EHRs) of 18,746 adult T2D patients (57% female) who initiated GLP‑1 RA, SGLT2i, or DPP4i therapies on or after January 2018.

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, to a rare eye disease that may cause vision loss.

Lower risks for anxiety disorders, substance use disorders, cognitive deficits seen for those undergoing metabolic and bariatric surgery ...

LA-GLP1 RA Effects on the Risk of Medullary Thyroid Cancer GLP-1 receptors are present in several tissues including the pancreas, intestine, stomach, nervous system and others.

Continuous Protein Sensor for Sarcopenia Management During GLP-1 RA Therapy Presented on Sunday, June 22 at 12:30 – 1:30 PM CT About the ADA's Scientific Sessions ...

Dose-dependent, marked reductions in food intake and significant weight loss observed in obese cynomolgus monkeys BMF-650 compared favorably to published data of a leading GLP-1 RA candidate IND ...

About BMF-650 BMF-650 is an investigational, next-generation oral small-molecule GLP-1 RA being developed by Biomea Fusion for the treatment of obesity. Related to the broader orforglipron chemotype, ...